Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
KalVista Pharmaceuticals, Inc. (KALV)
:KALV
RESEARCH TOOLSreports
Holding KALV?
Track your performance easily
KALV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$7.30 - $16.88
Previous CloseN/A
Volume49.40K
Average Volume (3M)354.81K
Market Cap
$407.70M
Enterprise Value$350.00M
Total Cash (Recent Filing)$30.95M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Mar 12, 2025EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.64
Shares Outstanding49,417,988
10 Day Avg. Volume275,796
30 Day Avg. Volume354,808
Standard Deviation0.25
R-Squared0.03
Alpha0.00665
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.86
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.19
Forecast
1Y Price Target
$25.17Price Target Upside203.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
KalVista Pharmaceuticals News
PremiumCompany Announcements
KalVista Pharmaceuticals Appoints New COO Amid Strategic Growth
PremiumCompany Announcements
KalVista Pharmaceuticals Reports Progress in HAE Treatment
PremiumPre-Earnings
Is KALV a Buy, Before Earnings?Bulls Say, Bears Say
Bulls Say
Financial PositionTwo strategic financings have been disclosed, raising $160M, which places the company in a comfortable position for the launch of sebetralstat.
Market PotentialAs the first oral on-demand HAE therapy, sebetralstat is expected to see strong demand, indicating a transformative potential in the market.
Regulatory ProgressSebetralstat FDA review is progressing smoothly, with recent data showing consistent safety and efficacy, which bodes well for regulatory prospects.
Bears Say
CompetitionInvestors are possibly spooked by minor nuances of efficacy data as well as emerging competition from a second oral on-demand hereditary angioedema (HAE) drug, Pharvaris' deucrictibant.
Pipeline DevelopmentRest of pipeline is still in preclinical stages.
Stock Price TargetThe price target was adjusted to $28 from $32 to reflect the dilution associated with the financing.
---
Ownership Overview
11.27% Insiders
15.23% Mutual Funds
0.15% Other Institutional Investors
63.54% Public Companies and Individual Investors
KALV FAQ
What was KalVista Pharmaceuticals, Inc.’s price range in the past 12 months?
KalVista Pharmaceuticals, Inc. lowest stock price was $7.30 and its highest was $16.88 in the past 12 months.
What is KalVista Pharmaceuticals, Inc.’s market cap?
KalVista Pharmaceuticals, Inc.’s market cap is $407.70M.
When is KalVista Pharmaceuticals, Inc.’s upcoming earnings report date?
KalVista Pharmaceuticals, Inc.’s upcoming earnings report date is Mar 12, 2025 which is in 52 days.
How were KalVista Pharmaceuticals, Inc.’s earnings last quarter?
KalVista Pharmaceuticals, Inc. released its earnings results on Dec 05, 2024. The company reported -$0.91 earnings per share for the quarter, missing the consensus estimate of -$0.908 by -$0.002.
Is KalVista Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts KalVista Pharmaceuticals, Inc.’s price is currently Undervalued.
Does KalVista Pharmaceuticals, Inc. pay dividends?
KalVista Pharmaceuticals, Inc. does not currently pay dividends.
What is KalVista Pharmaceuticals, Inc.’s EPS estimate?
KalVista Pharmaceuticals, Inc.’s EPS estimate is -0.87.
How many shares outstanding does KalVista Pharmaceuticals, Inc. have?
KalVista Pharmaceuticals, Inc. has 49,417,988 shares outstanding.
What happened to KalVista Pharmaceuticals, Inc.’s price movement after its last earnings report?
KalVista Pharmaceuticals, Inc. reported an EPS of -$0.91 in its last earnings report, missing expectations of -$0.908. Following the earnings report the stock price went down -4.228%.
Which hedge fund is a major shareholder of KalVista Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in KALV
---
KalVista Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.17 (203.25% Upside)
$25.17 (203.25% Upside)
Blogger Sentiment
Bullish
KALV Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 554.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.15%
12-Months-Change
Fundamentals
Return on Equity
-125.90%
Trailing 12-Months
Asset Growth
15.92%
Trailing 12-Months
Company Description
KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.
---
KALV Stock 12 Month Forecast
Average Price Target
$25.17
▲(203.25% Upside)
Technical Analysis
Aurinia Pharmaceuticals
―
Sangamo Biosciences
―
Omeros
―
Annovis Bio
―
PDS Biotechnology
―
Amicus
―
Best Analysts Covering KALV
1 Year
1 Year Success Rate
10/21 ratings generated profit
1 Year Average Return
+2.44%
reiterated a buy rating last month
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of +2.44% per trade.
---